v3.26.1
Summary of Significant Accounting Policies (Details) - USD ($)
 3 Months Ended
Mar. 31, 2026
Mar. 31, 2025
Feb. 13, 2026
Dec. 31, 2025
Summary of Significant Accounting Policies [Line Items]        
Accounts receivable $ 11,974     $ 0
Allowance for doubtful accounts 0     0
Change in the fair value of the Evofem warrants (25,004)    
Impairment fixed assets $ 32,275      
Derivative shares (in Shares)     698,818  
Percentage of additional shares 50.00%      
Derivative warrants $ 698,818      
Patent licensing fees 44,595 101,340    
Research and development expenses 1,047,083 1,209,205    
Sales and marketing costs 50,920    
Net loss attributable to non-controlling interest (241,475) $ (242,156)    
Billed Revenues [Member]        
Summary of Significant Accounting Policies [Line Items]        
Accounts receivable 3,574     0
Unbilled Revenues [Member]        
Summary of Significant Accounting Policies [Line Items]        
Accounts receivable $ 8,400     $ 0
Pearsanta, Inc. [Member]        
Summary of Significant Accounting Policies [Line Items]        
Owns percentage 97.00%      
Series A-1 Convertible Preferred Stock [Member]        
Summary of Significant Accounting Policies [Line Items]        
Derivative shares (in Shares) 20,552      
Series B-1 Convertible Preferred Stock [Member]        
Summary of Significant Accounting Policies [Line Items]        
Derivative shares (in Shares) 2,689      
Series B-2 Convertible Preferred Stock [Member]        
Summary of Significant Accounting Policies [Line Items]        
Derivative shares (in Shares) 2,625      
Series C-1 Convertible Preferred Stock [Member]        
Summary of Significant Accounting Policies [Line Items]        
Derivative shares (in Shares) 896